References
- Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z.
- Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590–3.
- Nakanishi M, Tamagawa-Mineoka R, Arakawa Y, et al. Dupilumab-resistant facial erythema - Dermoscopic, histological and clinical findings of three patients. Allergol Int. 2021;70(1):156–158. doi:10.1016/j.alit.2020.07.001.
- Ahn J, Lee DH, Na CH, et al. Facial erythema in patients with atopic dermatitis treated with dupilumab - a descriptive study of morphology and aetiology. J Eur Acad Dermatol Venereol. 2022;36(11):2140–2152. doi:10.1111/jdv.18327.
- Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi:10.1111/jdv.16892.
- Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312–1315. doi:10.1001/jamadermatol.2019.2613.
- Kunsleben N, Rudrich U, Gehring M, et al. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol. 2015;135(7):1908–1911. doi:10.1038/jid.2015.106.
- Bridgewood C, Wittmann M, Macleod T, et al. T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17–type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142(10):2660–2667. doi:10.1016/j.jid.2022.03.013.
- Bridgewood C, Sharif K, Freeston J, et al. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatology (Oxford). 2021;60(5):2461–2466. doi:10.1093/rheumatology/keaa568.
- de Bruin-Weller M, Graham N, Pirozzi G, et al. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels?: reply from the authors. Br J Dermatol. 2018;178(5):1220–1221. doi:10.1111/bjd.16348.